Subtext

MTD

Mettler-Toledo International Inc.2024 Q1

SectorHealth Care
Date2024-05-10
Overall sentiment+10.8
Total words3340
CEO words728
CFO words1165
Analyst words863
Trailing EPS$38.50
Forward EPS est.$41.02
Forward P/E31.8
Sourceglopardo

Transcript

Each turn shows the speaker, their inferred role, the section, and that turn's net sentiment (×1000).

OperatorOperator+0.0

Thank you for standing by. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to the Mettler-Toledo First Quarter 2021 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Adam Uhlman, Head of Investor Relations. You may begin.

Adam UhlmanIR+13.2

Thank you, Sarah, and good morning, everyone. Thanks for joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer; and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call is being webcast and is available for replay on our website at mt.com A copy of the press release and the presentation that we will refer to on today's call is also available on the website.

Patrick KaltenbachCEO+27.4

Thanks, Adam, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our first quarter financial results, the details of which are outlined for you on Page 3 of our presentation. Overall, our results in the first quarter were much better than anticipated across most product categories and geographies. As discussed last quarter, we also had a benefit this quarter from recovering delayed product shipments from the fourth quarter.

Shawn VadalaCFO+16.4

Thanks, Patrick, and good morning, everyone. Sales in the quarter were $926 million, largely unchanged from prior year levels, both on a U.S. dollar basis and in local currencies. Our sales in the quarter benefited by approximately 6% from recovering nearly all of our previously disclosed delayed product shipments from the fourth quarter of 2023 above our guidance of an approximate benefit of 5%.

Patrick KaltenbachCEO-16.4

Thanks, Shawn. Let me start with some comments on our operating businesses, starting with Lab. As Shawn mentioned earlier, excluding the Q4 shipping delay benefits this quarter, local currency sales in our Laboratory business declined approximately 6% compared to last year. This was better than we anticipated, but we saw cautious spending patterns from our pharma and biopharma customers, especially in China.

OperatorOperator-71.4

[Operator Instructions] Your first question comes from the line of Dan Arias with Stifel.

Daniel AriasAnalyst+28.2

Shawn, the 50 bps-or-so that you're raising on the organic guide and then $0.20, I believe, on the bottom line, is that just feeling better about the logistics issue given that last quarter you sort of held back a bit given that it was early in the year or is that reflective of better results that you saw in 1Q and maybe the way that the year might unfold on demand?

Shawn VadalaCFO-11.5

Yes. Thanks, Dan. Thanks for the question. I think it's pretty much as you interpreted. It's largely related to doing a little bit better on the shipping delays that we had in Q4. Of course, we did a little bit better than that in terms of Q4 results in general. But even though we're not seeing any negative changes in the business. We also prefer to be a little bit cautious here until we get closer to the second half and have a little bit more visibility.

Daniel AriasAnalyst+12.0

And then maybe on the outlook for China. You pointed to continued challenges there in Q2. That's not exactly a surprise just given the way that things have unfolded this quarter. But it does sound like you expect some deceleration on what is an easier comp. I think the China comp gets 6 points easier next quarter. Is there something to that? And are you seeing any of the green shoots that have been discussed a little bit across the earnings cycle this quarter?

Patrick KaltenbachCEO-11.2

I can take this, Dan. Look, we have been definitely pleased that we have seen a somewhat better result in Q1 than we had expected. That said, we still expect it to be quite weak. I mean, as Shawn said, we'll have more than 20% decline in China second quarter based on the very tough compares we see against Q2 last year and the years before where there has been quite heavy investment in China. There was significant spending during COVID and also some, of course, inventory buildup, et cetera.

Shawn VadalaCFO-11.4

Yes. And just to maybe specifically address the comment about potential deceleration. I think it's important to also just look at maybe the multiyear comparisons here and if you just like look at the trends in terms of like dollar terms or renminbi terms, we're kind of hitting a high watermark a year ago in Q2 in terms of what we're lapping in terms of comps. So actually, the comp level that we have in Q2 is a more difficult comp than we had in the first quarter.

OperatorOperator-76.9

Your next question comes from the line of Jack Meehan with Nephron Research.

Jack MeehanAnalyst+19.2

I was wondering if you could just reflect on the first quarter a little bit. You posted flat local currency growth, you were guiding to down 4% to 6%, about a point came from better capture of logistics. Where did the rest of the upside come from? Can you just walk us through that?

Shawn VadalaCFO+63.5

Yes. Thanks, Jack. Hey, the rest of it, we -- despite being down 6%, excluding the shipping benefit, we're pleased we did better than expected. We kind of expected customers to start a little more cautiously this year. I think they did start cautiously, but we're glad that they didn't -- they weren't as cautious as maybe we were thinking at the beginning of the quarter.

Jack MeehanAnalyst+35.7

Great. And then do you mind just walking us through in terms of the guide for 2Q and the full year just by segment, what the expectations are?

Shawn VadalaCFO-16.7

Yes, sure. So let me start by business area. So our Q2 guide for Lab is to be down low single digit and for the full year to be up low- to mid-single digit. Product inspection, I don't know if I could also maybe add, if you exclude the shipping delay for the full year, that would be flattish.

OperatorOperator-76.9

Your next question comes from the line of Vijay Kumar with Evercore ISI.

Vijay KumarAnalyst+17.5

Congrats on a good Q1 execution. Maybe Shawn, for you, you beat Q1 by 500 basis points, right, at the minimum relative to your expectations. So that's annualized 125 basis points which you've raised guidance by 50 basis points, so did anything changed around the back half assumptions that makes you perhaps want to be a little bit more cautious?

Shawn VadalaCFO-46.9

No. Vijay, thanks for the question. No, I mean, we're not seeing -- I want to be clear, we're not seeing anything negative or new negative changes in the business. We just feel like it's still a little bit early in the year. We only have 1.5 months' worth of backlog, and we're just a little bit cautious here kind of going into the second quarter.

Vijay KumarAnalyst+0.0

Understood. And maybe Patrick, for you as a follow-up. Shawn mentioned visibility for back half and backlog, right? What is typical backlog for Mettler? When you say visibility, is that sort of being driven by funnel activity, customer conversations or are you hoping -- or do you have any expectations for China stimulus to play out in the back half?

Patrick KaltenbachCEO+15.6

Thanks for the question, Vijay. Look, as Shawn just said, we have about 1.5 months of backlog. So we have a pretty fast turnover in most of our businesses. When we look at the second half, again, the comps will get much easier for us based on what we have seen last year. So that, of course, implies a positive growth for the second half.

OperatorOperator-71.4

Your next question comes from the line of Michael Ryskin with Bank of America.

Michael RyskinAnalyst+13.9

I'm going to ask another one about market conditions as you go through the year because I think that's where there's the most interest. Just following up on your comments just there. Is there anything in particular you're looking for as you go through the year? I mean is it really just a matter of time of you don't want to call for an improvement until you're only about 3 or 6 months out?

Shawn VadalaCFO+15.2

Yes. Mike, this is Shawn. Maybe not to entirely repeat what we just said, but probably we'll echo it to a large degree. I think it comes back to this sitting on pretty much 1.5 months' worth of backlog. We do see good activity in our pipeline. As Patrick, I think, mentioned before, we are seeing order cycles being elongated a little bit in the first quarter.

Michael RyskinAnalyst+24.7

Okay. And I want to ask one on the P&L. I mean, 1Q earnings beat pretty handily, obviously, shipping, recovery and the underlying business being better, probably played a decent role in that. But could you sort of parse that out? I mean you gave a lot of color on what revenues would have been if it wasn't for the shipping recovery. Any color you can give on the P&L in terms of how much benefit was the EPS?

Shawn VadalaCFO+37.0

Yes. So in terms of the first quarter, as we kind of said, we benefited about 6% in terms of sales from the shipping delay benefit. Our expectation was that we were going to benefit about 5%. So we had a 1% benefit. So you can kind of maybe draw your own conclusions of what that would have meant or not. But maybe more importantly, if you just take that reported number of sales in Q1 and you look at our guidance for Q2, regardless of shipping delay benefit. With that benefit, the reported number is actually a very similar dollar number sequentially to what we see in the second quarter.

OperatorOperator-83.3

Your next question comes from the line of Rachel Vatnsdal with JPMorgan.

Rachel Vatnsdal OlsonOther+12.3

So I want to dig into the Industrial performance in the quarter. You mentioned some strength in Americas and 1Q on some project level activity, but then you also said that you expect core industrial to be down high singles in 2Q. So can you just kind of walk us through the drivers of that core Industrial business in the first half of the year? Were there any one-timers that we need to be aware of in 1Q, for example?

Patrick KaltenbachCEO+14.7

Thank you, Rachel, and I'll start and maybe let Shawn chime in as well. Looking at it, we are very proud of the performance of our Industrial business. I think it comes down to really the outstanding portfolio enhancements we have made over the last year. I mentioned the Industry 360 terminal and other things we launched driving productivity for our customers, and they really pick it up nicely.

Shawn VadalaCFO-13.9

Yes. Maybe just to get to the other part of your question, Rachel. The first quarter in the U.S., certainly, that project activity is lumpy. And so we certainly will not see that in the second quarter. So there's an element of that. And then maybe the other point I make here is that in core Industrial, it has a larger mix of business weighted towards China versus our other businesses.

Rachel Vatnsdal OlsonOther-11.2

And then just for my follow-up, I want to dig into some of the biopharma commentary that you gave. So you mentioned some of slower spending to start of the year, we've been hearing that across the sector this earnings season. But can you just unpack for us what does guidance assume in terms of those biopharma customer budget starting to open up? And then have you seen any activity level from biopharma customers pick up in April and then early May here from that group as well?

Patrick KaltenbachCEO+0.0

Well, look, when we talk about biopharma, I think the business we really focus on here is our Process Analytics business. Biopharma definitely still has been soft in the first quarter, and we also expected given the year, biopharma customers to be soft in the second quarter as well.

Shawn VadalaCFO+32.3

And the other part of biopharma, of course, pipettes and we certainly have seen improvement in pipettes relative to some of the destocking issues that we were dealing with last year.

OperatorOperator-76.9

Your next question comes from the line of Matt Sykes with Goldman Sachs.

Matthew SykesAnalyst+19.2

Patrick, maybe -- and sorry if I've missed it, but maybe just some commentary around the services business. I think you mentioned it was strong in Q1, but just any expectations and progress that you've made on your services initiative over the course of this quarter and your expectations for the full year?

Patrick KaltenbachCEO+29.4

Yes. Very good. Thanks. Matt, I mean, again, we are very proud about the performance of our service business. We had 6% growth in the first quarter against a very strong growth in the first quarter last year. We see strong demand for our services. We continue to build out the service portfolio that we can deliver to our customers. We compete extremely well. We still have a lot of opportunity with the installed base that we have out there, connecting more of our services to the installed base, and we have dedicated marketing programs in place to connect more of the business.

Matthew SykesAnalyst-22.7

And then just maybe a little more color on Europe. I know you're guiding to low-single digits for Q2 and mid-single digits for the full year, but you've been cautious on Europe for some time. You kind of reiterated that caution again.

Shawn VadalaCFO+55.6

Yes. Matt, this is Shawn, maybe I'll take that one. So we're very pleased with the execution from our team in Europe. We have our most direct sales organization there in terms of direct channel to the customer. And I tend to think we always feel the best benefit of our Spinnaker sales and marketing programs in Europe. So I think that's one of the things that we feel very good about.

OperatorOperator-83.3

Your next question comes from the line of Catherine Schulte with Baird.

Catherine RamseyOther+0.0

First, great to see the recapture of the shipping delays coming in above your expectations and recapturing pretty much all of that lost revenue. Just when it comes to the new logistics provider, would you say that situation is fully resolved? You got the protocols and processes in place to move smoothly going forward?

Patrick KaltenbachCEO+50.5

Yes. Thanks, Catherine. I'm really happy how the team performed in Q1 and how we could resolve that issue that we had in Q4. Actually, I'm looking at all the major KPIs that we have bought I would say, today, we are in a very, very good situation. We can, of course, keep a very close eye on it because a couple of months of great performance is not enough for us to say, everything is locked down. But happy with the performance right now. Our team, our own team has been really deeply engaged with fixing the situation.

Catherine RamseyOther-29.9

And then maybe on the second quarter guide, it's implying a slower sequential increase than what you've typically seen historically. So can you just talk through any areas of conservatism that you feel are in the second quarter guide? It looks like maybe on the Industrial side is where that's a slower uptick sequentially than historically, but curious if you could just give some more color there.

Shawn VadalaCFO+0.0

Yes, sure, Catherine, maybe I take that one. So of course, there was the shipping delay benefit in Q1, but I -- but if you exclude that, I think like the multiyear CAGRs still look pretty similar between Q2 and Q1.

OperatorOperator-83.3

Your next question comes from the line of Patrick Donnelly with Citi.

Patrick DonnellyAnalyst+38.5

I want to follow up on, I think, as Rachel asking about kind of the underlying improvement as we work our way through the year, I think that was biopharma, can you talk about China, just the assumptions there. Obviously, the comps get easier, it sounds like 2Q will be down 20%-plus.

Shawn VadalaCFO+0.0

Yes. I mean I think if you like look at our -- like if you look at our full year guide for China, we're still expecting to be down high-single digit. I think if you try to break it out between the businesses, maybe on a full year basis, Industrial might be a little bit better than that, than Lab. But I think that's largely because of what we saw in Q1.

Patrick KaltenbachCEO+39.2

Yes. And we see a very good engagement with customers in China as well. The sales team has really good engagement. We monitor very closely. So there's a lot of customer interest out there that I think will help us also to get back to that growth in the second half.

Shawn VadalaCFO+26.0

Yes. And then to kind of feed off that, our team there has just always been such an agile team to pivot to where the growth opportunities are. And certainly, that was a topic we were talking about throughout this week with our -- at the executive level as just some of the programs that they're doing locally to identify those pockets of growth and go after them. So we feel like we're well positioned as things improve.

Patrick DonnellyAnalyst+0.0

Okay. That's helpful. And then, Shawn, maybe just on the margin build. Can you just talk about the pricing piece in the quarter and as you work your way through the year? And then similarly, just how you're thinking about the cost base given, again, if you are still a little bit of a softer macro, how nimble you're being on the cost side would be helpful?

Shawn VadalaCFO+32.3

Yes. So I kind of mentioned earlier in one of the other questions. Pricing came in pretty much as expected in the quarter at 2%. We're still kind of holding our guide for the full year on pricing at 2%. Of course, we're going to try to do better than that. I think all the things we're doing on innovation certainly continues to enhance our value proposition. And so that always helps. I see good execution on this topic as well, too. So we'll see how it plays out for the rest of the year.

OperatorOperator-76.9

Your next question comes from the line of Joshua Waldman with Cleveland Research.

Joshua WaldmanAnalyst+17.9

First, Patrick or Shawn, just to follow up on a previous theme. Any more color you can provide on what types of accounts started to open up in the latter part of Q1 or any customers that you'd point to that were sitting on the sidelines in '23 and maybe January that then started to improve?

Patrick KaltenbachCEO+60.6

Yes. Look, I mean I think we saw very good interest in our products and performance, as we said, better than expected throughout the end markets and product portfolio. If I would point to maybe one segment, it could be Food, actually, the food market, we saw really good interest for our product inspection business that also drove a little bit of the better performance there.

Joshua WaldmanAnalyst+23.3

And then, Shawn, maybe a related question on price. I guess I forget if you commented whether or not price is tracking kind of in line or how it is tracking versus expectations. But just curious if you could comment on price-risk expectations? And then in the recent past, you talked about using tough times to support share gains, any recent success stories or examples you could point to that you think are driving share gain, maybe supporting upside versus the guide year-to-date?

Shawn VadalaCFO+42.1

Joshua, maybe I'll take that one. So we'll start with price. So as I mentioned, price came in as expected in the quarter, it came in at 2%. So we were happy with that. We expect price to be 2% again in Q2 and for the full year, which is kind of consistent with our previous guidance. And as I kind of mentioned, we do feel very good about our value proposition, all the stuff we talked about earlier about innovation really strengthens that value proposition, so that helps to always support our pricing in the market.

OperatorOperator-117.6

This concludes the question-and-answer session. I'll turn the call to Adam Uhlman for closing remarks.

Adam UhlmanIR+25.0

Great. Thank you, everybody, for joining us this morning. If you have any follow-up questions, please feel free to reach out to me. And I hope you all have a great weekend. We'll talk to you soon. Thank you.

OperatorOperator+0.0

This concludes today's conference call. Thank you for joining. You may now disconnect.